BMY - Conference and earnings call announcements

Bristol Myers Squibb (NYSE:BMY) today announced that the company will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026. The company will take part in a fireside chat beginning at 2:00 p.m. ET. Investors and the general public are invited to listen to the session by visiting http://investor.bms.com. An archived edition of the session will be available following its conclusion. About Bristol Myers Squibb: Transforming Patients' Lives Through Science At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what's p

Bristol Myers Squibb (NYSE:BMY) today announced that the company will present at the Bank of America Securities Healthcare Conference 2026 on Thursday, May 14, 2026. The company will take part in a fireside chat beginning at 8:40 a.m. PT/11:40 a.m. ET. Investors and the general public are invited to listen to the session by visiting http://investor.bms.com. An archived edition of the session will be available following its conclusion. About Bristol Myers Squibb: Transforming Patients' Lives Through Science At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to defin

Bristol Myers Squibb (NYSE:BMY) today announced that the company will participate in the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026. The company will take part in a fireside chat beginning at 9:50 a.m. ET. Investors and the general public are invited to listen to the session by visiting http://investor.bms.com. An archived edition of the session will be available following its conclusion. About Bristol Myers Squibb: Transforming Patients' Lives Through Science At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what's possible for

Bristol Myers Squibb (NYSE:BMY) today announced that the company will present at J.P. Morgan's 44th Annual Healthcare Conference on Monday, January 12, 2026. The company's presentation and participation in a fireside chat will begin at 7:30 a.m. PST/10:30 a.m. ET. The event will be webcast simultaneously at http://investor.bms.com, with materials related to the presentation available at the start of the live webcast. A replay and archived edition of the presentation will be available following the conclusion of the event. About Bristol Myers Squibb: Transforming Patients' Lives Through Science At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicine

Bristol Myers Squibb (NYSE:BMY) today announced that the company will participate in Citi's 2025 Global Healthcare Conference on Thursday, December 4, 2025. The company will take part in a fireside chat beginning at 9:00 a.m. ET. Investors and the general public are invited to listen to the session by visiting http://investor.bms.com. An archived edition of the session will be available following its conclusion. About Bristol Myers Squibb: Transforming Patients' Lives Through Science At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what's possible for the

Bristol Myers Squibb (NYSE:BMY) today announced that, following the conclusion of the American Society of Hematology (ASH) Annual Meeting and Exposition, the company will hold a virtual investor event on Thursday, December 11, 2025, to highlight key Hematology programs. The company will host a webcast beginning at 9:00 a.m. ET, which is accessible here. Company representatives will provide investors and analysts an overview of the company's Hematology development strategy and review recent data. A replay of the webcast will be available at http://investor.bms.com approximately three hours after the event concludes. Materials related to the webcast will be available at http://investor.bms.

Bristol Myers Squibb (NYSE:BMY) today announced that the company will participate in the Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum on Tuesday, September 23, 2025. The company will take part in a fireside chat beginning at 9:40 a.m. ET. Investors and the general public are invited to listen to the session by visiting http://investor.bms.com. An archived edition of the session will be available following its conclusion. About Bristol Myers Squibb: Transforming Patients' Lives Through Science At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are pur

Bristol Myers Squibb (NYSE:BMY) today announced that the company will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on Monday, September 8, 2025. The company will take part in a fireside chat beginning at 8:30 a.m. ET. Investors and the general public are invited to listen to the session by visiting http://investor.bms.com. An archived edition of the session will be available following its conclusion. About Bristol Myers Squibb: Transforming Patients' Lives Through Science At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define wha

Bristol Myers Squibb (NYSE:BMY) today announced that the company will participate in the Goldman Sachs 46th Annual Global Healthcare Conference on Wednesday, June 11, 2025. The company will take part in a fireside chat beginning at 10:00 a.m. ET. Investors and the general public are invited to listen to the session by visiting http://investor.bms.com. An archived edition of the session will be available following its conclusion. About Bristol Myers Squibb: Transforming Patients' Lives Through Science At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define wh

Bristol Myers Squibb (NYSE:BMY) today announced that the company will participate in the Bernstein 41st Annual Strategic Decisions Conference on Wednesday, May 28, 2025. The company will take part in a fireside chat beginning at 3:30 p.m. ET. Investors and the general public are invited to listen to the session by visiting http://investor.bms.com. An archived edition of the session will be available following its conclusion. About Bristol Myers Squibb: Transforming Patients' Lives Through Science At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what's pos

Bristol Myers Squibb (NYSE:BMY) today announced that the company will participate in two upcoming investor conferences in March 2025. The company will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on March 4, 2025, at 2:30 p.m. ET. In addition, the company will take part in a fireside chat at the Leerink Partners 2025 Global Healthcare Conference on March 12, 2025, at 11:20 a.m. ET. Investors and the general public are invited to listen to both sessions at their respective times by visiting http://investor.bms.com. An archived edition of each session will be available following its conclusion. About Bristol Myers Squibb Bristol Myers Squibb is a g

Bristol Myers Squibb (NYSE:BMY) today announced that the company will present at J.P. Morgan's 43rd Annual Healthcare Conference on Monday, January 13, 2025. The company's presentation and participation in a fireside chat will begin at 7:30 a.m. PT/10:30 a.m. ET. The event will be webcast simultaneously at http://investor.bms.com, with materials related to the presentation available at the start of the live webcast. A replay and archived edition of the presentation will be available following the conclusion of the event. About Bristol Myers Squibb Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that he

Bristol Myers Squibb (NYSE:BMY) today announced that the company will participate in Citi's 2024 Global Healthcare Conference. Christopher Boerner, Ph.D., board chair and chief executive officer, will take part in a fireside chat on December 3, 2024. He will answer questions about the company beginning at 8:00 a.m. ET. Investors and the general public are invited to listen to a live webcast of the session by visiting http://investor.bms.com. An archived edition of this session will be available following its conclusion. About Bristol Myers Squibb Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that hel

Bristol Myers Squibb (NYSE:BMY) today announced that the company will participate in two upcoming investor conferences in November 2024. Samit Hirawat, M.D., Executive Vice President, Chief Medical Officer and Head of Development, and Robert Plenge, M.D., Ph.D., Executive Vice President, Chief Research Officer, will take part in a fireside chat at Guggenheim's Inaugural Healthcare Innovation Conference. They will answer questions about the company beginning at 10:00 a.m. ET on November 11, 2024. David Elkins, Executive Vice President, Chief Financial Officer, will participate in a fireside chat at the 2024 Jefferies London Healthcare Conference on November 19, 2024. He will answer questio

With cancer patients top of mind, teams of Bristol Myers Squibb (NYSE:BMY) employees will relay Coast 2 Coast 4 Cancer (C2C4C) this year and cycle from Oregon to New Jersey with the goal of raising $1 million in support of the V Foundation for Cancer Research. Since the ride's inception in 2014, Bristol Myers Squibb employees – many of whom have been personally impacted by cancer – have come together to fundraise, resulting in more than $12.7 million in donations for cancer research in North America. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240830627870/en/Coast 2 Coast 4 Cancer Riders kicking off 3,000 mile bike ride from

Bristol Myers Squibb (NYSE:BMY) today announced that the company will participate in two upcoming investor conferences in September 2024. Christopher Boerner, Ph.D., Board Chair and Chief Executive Officer, and David Elkins, Executive Vice President, Chief Financial Officer, will take part in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on September 5, 2024. They will answer questions about the company beginning at 1:05 p.m. ET. Adam Lenkowsky, Executive Vice President, Chief Commercialization Officer, will participate in a fireside chat at the 2024 Wells Fargo Healthcare Conference on September 6, 2024. He will answer questions about the company beginn

Bristol Myers Squibb (NYSE:BMY) today announced that the company will participate in Virtual Targeted Protein Degradation Day hosted by UBS. Robert Plenge, M.D., Ph.D., Executive Vice President, Chief Research Officer and Head of Research, will take part in a fireside chat on Monday, July 15, 2024. He will answer questions about the company beginning at 11:00 a.m. ET. Investors and the general public are invited to listen to a live webcast of the session by visiting http://investor.bms.com. An archived edition of the session will be available following its conclusion. About Bristol Myers Squibb Company Bristol Myers Squibb is a global biopharmaceutical company whose mission is to di

Bristol Myers Squibb (NYSE:BMY) today announced that the company will participate in the Goldman Sachs 45th Annual Global Healthcare Conference. Christopher Boerner, Ph.D., Board Chair and Chief Executive Officer, will take part in a fireside chat on Tuesday, June 11, 2024. He will answer questions about the company beginning at 11:20 a.m. ET. Investors and the general public are invited to listen to a live webcast of the session by visiting http://investor.bms.com. An archived edition of the session will be available following its conclusion. About Bristol Myers Squibb Company Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop, and deli

Bristol Myers Squibb (NYSE:BMY) today announced that the company will participate in two upcoming investor conferences in May 2024. Ben Hickey, President, RayzeBio, Head of Mirati, will take part in a fireside chat at the Guggenheim Healthcare Talks Radiopharmaceuticals Day on Monday, May 13, 2024. He will answer questions about the company beginning at 11:00 a.m. ET. David Elkins, Executive Vice President, Chief Financial Officer, will participate in a fireside chat at the 2024 Bank of America Global Healthcare Conference on Wednesday, May 15, 2024. He will answer questions about the company beginning at 11:20 a.m. PT/2:20 p.m. ET. Investors and the general public are invited to list

Bristol Myers Squibb (NYSE:BMY) today announced an update following the initial analysis of results from the first of two induction studies in the Phase 3 YELLOWSTONE clinical trial program evaluating Zeposia (ozanimod) in adult patients with moderate to severe active Crohn's disease. The study did not meet its primary endpoint of clinical remission at Week 12. The safety profile of Zeposia in this study was consistent with that observed in previously reported trials. The company will complete a full evaluation of the YELLOWSTONE trial data and work with investigators to share the results with the scientific community in the future. "To date, no S1P modulator has shown an effect in a Ph

Bristol Myers Squibb (NYSE:BMY) today announced that the company will participate in two upcoming investor conferences in March 2024. Samit Hirawat, M.D., executive vice president, chief medical officer, Drug Development, will take part in a fireside chat at the Leerink Partners Global Biopharma Conference 2024 in Miami Beach, Florida, on Wednesday, March 13, 2024. He will answer questions about the company beginning at 10:00 a.m. ET. Lynelle Hoch, president, Cell Therapy Organization, and Wendy Short Bartie, senior vice president, U.S. Hematology and Oncology, will participate in a fireside chat at the Barclays 26th Annual Global Healthcare Conference in Miami Beach, Florida, on Thursd

Bristol Myers Squibb (NYSE:BMY) today announced that the company will participate in the TD Cowen 44th Annual Health Care Conference in Boston, Massachusetts, on Monday, March 4, 2024. Roland Chen, M.D., senior vice president, Immunology, Cardiovascular & Neuroscience development, will answer questions about the company during a fireside chat at 9:50 a.m. ET. Investors and the general public are invited to listen to a live webcast of the session here. An archived edition of the session will be available following its conclusion. About Bristol Myers Squibb Company Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop, and deliver innovative me

Bristol Myers Squibb (NYSE:BMY) today announced that the company will present at J.P. Morgan's 42nd Annual Healthcare Conference in San Francisco, California, on Monday, January 8, 2024. Christopher Boerner, Ph.D., chief executive officer, will make a formal presentation and answer questions about the company at 7:30 a.m. PST/10:30 a.m. EST. The event will be webcast simultaneously at http://investor.bms.com with materials related to the presentation available at the start of the live webcast. A replay and archived edition of the presentation will be available following the event. About Bristol Myers Squibb Company Bristol Myers Squibb is a global biopharmaceutical company whose missi

Bristol Myers Squibb (NYSE:BMY) today announced that the company will participate in the 2024 Goldman Sachs Healthcare C-Suite Unscripted Conference in New York City on Thursday, January 4, 2024. Adam Lenkowsky, executive vice president, chief commercialization officer, will answer questions about the company during a fireside chat at 11 a.m. ET. Investors and the general public are invited to listen to a live webcast of the session here. An archived edition of the session will be available following its conclusion. About Bristol Myers Squibb Company Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop, and deliver innovative medicines that

For Immediate Release: November 17, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, to mark the 15th anniversary of the FDA foreign offices, the FDA published an interview with Susan Winckler, who was FDA chief of staff when the first office was opened in Beijing on November 19, 2008. Winckler is now CEO of the Reagan-Udall Foundation

Bristol Myers Squibb (NYSE:BMY) today announced that the company will participate in the 2023 Jefferies London Healthcare Conference in London, England, on Thursday, November 16, 2023. Tim Power, vice president, head of investor relations, will answer questions about the company during a fireside chat at 9:30 a.m. GMT (U.K.). Investors and the general public are invited to listen to a live webcast of the session here. An archived edition of the session will be available following its conclusion. About Bristol Myers Squibb Company Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop, and deliver innovative medicines that help patients prevail

Bristol Myers Squibb (NYSE:BMY) today announced that the company will participate in the 2023 UBS BioPharma Conference in Miami Beach, Florida, on Wednesday, November 8, 2023. Lynelle Hoch, president, cell therapy organization, will answer questions about the company during a fireside chat at 8:00 a.m. ET. Investors and the general public are invited to listen to a live webcast of the session here. An archived edition of the session will be available following its conclusion. About Bristol Myers Squibb Company Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseas

65 physicians comprise Cohort III, bringing the total to 179 participants in the program's third year The Bristol Myers Squibb Foundation (BMS Foundation), together with Virginia Commonwealth University (VCU), the American Association for Cancer Research (AACR), Gilead Sciences, Inc., and Amgen today announced that an additional 65 physicians have been selected to receive the Robert A. Winn Diversity in Clinical Trials Career Development Award (Winn CDA). The broader Robert A. Winn Diversity in Clinical Trials Award Program (Winn Award Program) aims to train, develop and mentor more than 308 clinical trialists and 308 medical students by 2027 who are diverse or who have a demonstrated com

For Immediate Release: October 17, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA’s The Center for Drug Evaluation and Research (CDER) announced that the center is soliciting public comments to understand the state of innovation in clinical trial design and conduct. CDER is gathering information from internal and external sta

Bristol Myers Squibb (NYSE:BMY) today announced that the company will participate in the Morgan Stanley 21st Annual Global Healthcare Conference in New York City on Monday, September 11, 2023. Giovanni Caforio, M.D., board chair and chief executive officer, and Chris Boerner, Ph.D., executive vice president and chief operating officer, will answer questions about the company during a fireside chat at 8 a.m. EDT. Investors and the general public are invited to listen to a live webcast of the session here. An archived edition of the session will be available following the session's conclusion. About Bristol Myers Squibb Bristol Myers Squibb is a global biopharmaceutical company whose mi

New artificial intelligence algorithm for earlier detection and management of hypertrophic cardiomyopathy Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced it has received a De Novo approval by the U.S. Food and Drug Administration (FDA) for its Viz HCM module, a hypertrophic cardiomyopathy (HCM) artificial intelligence (AI) detection algorithm, creating a new regulatory category for cardiovascular machine learning-based notification software. The deployment of the algorithm is financially supported by a multi-year agreement with Bristol Myers Squibb (NYSE:BMY) announced in March. With the use of Viz HCM, which is integrated into the Viz

Bristol Myers Squibb (NYSE:BMY) today announced that the company will participate in the following investor conferences in June 2023: Company executives will take part in a fireside chat at the 2023 Jefferies Healthcare Conference in New York, New York on June 8, 2023. They will answer questions about the company at 9:00 a.m. ET. Bristol Myers Squibb executives will also participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference on June 13, 2023, in Dana Point, California. They will answer questions about the company at 8:40 a.m. PT/11:40 a.m. ET. Investors and the general public are invited to listen to a live webcast of both sessions during their re

First disclosure from Phase 3 COMMANDS study, selected for both ASCO's official press program and EHA's plenary session, highlights potential of Reblozyl (luspatercept-aamt) as first-line treatment of anemia in very low- to intermediate-risk myelodysplastic syndromes First presentation of results from primary analysis of TRANSCEND CLL 004 demonstrates benefit of Breyanzi (lisocabtagene maraleucel) in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma New TRIDENT-1 data reinforce potential of precision medicine repotrectinib in patients with locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC), including those with central

Bristol Myers Squibb (NYSE:BMY) today announced that the company will participate in the Bank of America Securities 2023 Healthcare Conference in Las Vegas, Nevada on Tuesday, May 9, 2023. Adam Lenkowsky, Executive Vice President, Chief Commercialization Officer, will answer questions about the company at 8:40 a.m. PT/11:40 a.m. ET. Investors and the general public are invited to listen to a live webcast of the session at http://investor.bms.com. An archived edition of the session will be available later that day. About Bristol Myers Squibb Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patien

Bristol Myers Squibb (NYSE:BMY) today announced that the company will take part in a fireside chat at Cowen's 43rd Annual Health Care Conference on Tuesday, March 7, 2023. Samit Hirawat, M.D., Executive Vice President, Chief Medical Officer, Head of Development, will answer questions about the company at 9:50 a.m. ET. Investors and the general public are invited to listen to a live webcast of the session at http://investor.bms.com. An archived edition of the session will be available later that day. About Bristol Myers Squibb Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over se

Bristol Myers Squibb (NYSE:BMY) today announced that the company will take part in a fireside chat at the Guggenheim Healthcare Talks 2023 Oncology Conference on Thursday, February 9, 2023. Chris Boerner, Ph.D., Executive Vice President, Chief Commercialization Officer, will answer questions about the company at 1:00 p.m. ET. Investors and the general public are invited to listen to a live webcast of the session at http://investor.bms.com. An archived edition of the session will be available later that day. About Bristol Myers Squibb Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail

Bristol Myers Squibb (NYSE:BMY) today announced that the company will present at J.P. Morgan's 41st Annual Healthcare Conference on Monday, January 9, 2023. Giovanni Caforio, M.D., Board Chair and Chief Executive Officer will make a formal presentation and answer questions about the company at 7:30 a.m. PST/10:30 a.m. EST. The event will be webcast simultaneously at http://investor.bms.com with materials related to the presentation available at the start of the live webcast. A replay and archived edition of the presentation will be available following the event. About Bristol Myers Squibb Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and

Bristol Myers Squibb (NYSE:BMY) today announced that the company will take part in a fireside chat at the Wolfe Research Healthcare Conference on Wednesday, November 16, 2022 in New York City. Chris Boerner, Ph.D., Executive Vice President, Chief Commercialization Officer, will answer questions about the company at 3:20 p.m. ET. Investors and the general public are invited to listen to a live webcast of the session at http://investor.bms.com. An archived edition of the session will be available later that day. About Bristol Myers Squibb Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prev

Bristol Myers Squibb (NYSE:BMY) today announced that the company will take part in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Monday, September 12, 2022 in New York City. Chris Boerner, Ph.D., Executive Vice President, Chief Commercialization Officer and Samit Hirawat, M.D., Executive Vice President, Chief Medical Officer, Global Drug Development will answer questions about the company at 8:10 a.m. ET. Investors and the general public are invited to listen to a live webcast of the session at http://investor.bms.com. An archived edition of the session will be available later that day. About Bristol Myers Squibb Bristol Myers Squibb is a global biopha

Bristol Myers Squibb (NYSE:BMY) today announced that the company will take part in a fireside chat at Citi's 17th Annual BioPharma Conference on Thursday, September 8, 2022 in Boston, Massachusetts. Company executives will answer questions about the company at 8:50 a.m. ET. Investors and the general public are invited to listen to a live webcast of the session at http://investor.bms.com. An archived edition of the session will be available later that day. About Bristol Myers Squibb Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Br

Bristol Myers Squibb (NYSE:BMY) today announced that the company will host a virtual Investor Event on Sunday, August 28, 2022, at 7:00 p.m. CET/ 1:00 p.m. ET to discuss data from the AXIOMATIC-SSP Phase 2 trial of milvexian in secondary stroke prevention presented at the European Society of Cardiology Congress 2022 in Barcelona, Spain. Company executives will provide an overview of data presented and address questions from investors and analysts. Investors and the general public are invited to listen to a live webcast of the session at http://investor.bms.com. Material related to the company's presentation will be available at the same website at the start of the live webcast. An archive

Bristol Myers Squibb (NYSE:BMY) today announced that the company will take part in a fireside chat at Goldman Sachs' 43rd Annual Global Healthcare Conference in Rancho Palos Verdes, California on Wednesday, June 15, 2022. Adam Lenkowsky, Senior Vice President and General Manager, U.S. Commercialization, will answer questions about the company at 9:20 a.m. PT/12:20 p.m. ET. Investors and the general public are invited to listen to a live webcast of the session at http://investor.bms.com. Material related to the company's presentation will be available at the same website at the start of the live webcast. An archived edition of the session will be available later that day. About Bristol Mye

Bristol Myers Squibb (NYSE:BMY) today announced that the company will take part in a fireside chat at Bernstein's 38th Annual Strategic Decisions Conference in New York, New York on Thursday, June 2, 2022. Giovanni Caforio, M.D., Board Chair and Chief Executive Officer and Samit Hirawat, Executive Vice President, Chief Medical Officer, Global Drug Development, will answer questions about the company at 8:00 a.m. ET. Investors and the general public are invited to listen to a live webcast of the session at http://investor.bms.com. Material related to the company's presentation will be available at the same website at the start of the live webcast. An archived edition of the session will be

Bristol Myers Squibb (NYSE:BMY) today announced that the company will take part in a fireside chat at the Bank of America Securities 2022 Healthcare Conference in Las Vegas, Nevada on Wednesday, May 11, 2022. Adam Lenkowsky, Senior Vice President and General Manager, U.S. Commercialization, will answer questions about the company at 12:00 p.m. PT/3:00 p.m. ET. Investors and the general public are invited to listen to a live webcast of the session at http://investor.bms.com. Material related to the company's presentation will be available at the same website at the start of the live webcast. An archived edition of the session will be available later that day. About Bristol Myers Squibb Br

Bristol Myers Squibb (NYSE:BMY) and Nektar Therapeutics (NASDAQ:NKTR) today announced an update following the first analysis of the Phase 3 PIVOT IO-001 study evaluating the doublet therapy of bempegaldesleukin in combination with Opdivo (nivolumab) compared to Opdivo monotherapy as a first-line treatment for previously untreated unresectable or metastatic melanoma. Following a review of the study for efficacy and safety by an independent Data Monitoring Committee (DMC), Bristol Myers Squibb and Nektar were informed that the study did not meet the primary endpoints of progression-free survival (PFS) and objective response rate (ORR) as assessed by Blinded Independent Central Review (BICR).

Bristol Myers Squibb (NYSE:BMY) today announced its participation in the following investor conferences on Wednesday, March 16, 2022: Rupert Vessey, MA, BM, BCh, FRCP, DPhil, Executive Vice President and President, Research and Early Development, will take part in a fireside chat at Guggenheim Healthcare Talks, Targeted Protein Degradation Day. He will answer questions about the company at 10:15 a.m. ET. Samit Hirawat, Executive Vice President, Chief Medical Officer, Global Drug Development, will take part in a fireside chat at the Barclays' 2022 Global Healthcare Conference in Miami, Florida. He will answer questions about the company at 1:35 p.m. ET. Investors and the general public ar

Bristol Myers Squibb (NYSE:BMY) today announced that the company will present at J.P. Morgan's 40th Annual Virtual Healthcare Conference on Monday, January 10, 2022. Giovanni Caforio, M.D., Board Chair and Chief Executive Officer will make a formal presentation and answer questions about the company at 7:30 a.m. ET. The event will be webcast simultaneously at http://investor.bms.com with materials related to the presentation available at the start of the live webcast. A replay and archived edition of the presentation will be available following the event. About Bristol Myers Squibb Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and delive

The reported prevalence of HCM ranges from 1 in 200* to 1 in 500† people in the general population, however it is estimated that many patients remain undiagnosed, underscoring need for increased awareness and education Jared Butler, professional basketball player living with HCM, to partner on education campaign and share his diagnosis story CouldItBeHCM.com offers educational content and downloadable resources to increase awareness of the disease and help people experiencing possible signs and symptoms talk to their doctor and ask if they should see a cardiologist Bristol Myers Squibb today announced the launch of Could It Be HCM?, an education campaign to help raise awareness of hypert

Bristol Myers Squibb (NYSE:BMY) today announced that the company will hold an Investor Event in New York City on Tuesday, November 16, 2021 at 9:30 a.m. ET. Giovanni Caforio, M.D., Board Chair and Chief Executive Officer, will be joined by members of the company's leadership team to discuss the Company's strategy, pipeline and business opportunities. The event will also be simultaneously webcast at http://investor.bms.com, with materials related to the presentation available at the start of the live webcast. A replay and archived edition of the presentation will be available following the event. About Bristol Myers Squibb Bristol Myers Squibb is a global biopharmaceutical company whose m

Bristol Myers Squibb (NYSE:BMY) today announced that the company will participate in a fireside chat at the Morgan Stanley 19th Annual Global Healthcare Virtual Conference, which will be webcast on Tuesday, September 14, 2021. Giovanni Caforio, M.D., Board Chair and Chief Executive Officer, will answer questions about the company at 8 a.m. ET. Investors and the general public are invited to listen to a live webcast of the session at http://investor.bms.com. An archived edition of the session will be available later that day. About Bristol Myers Squibb Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that hel

NEW YORK--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in a fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Virtual Conference, which will be webcast on Thursday, June 10, 2021. Chris Boerner, Ph.D., Executive Vice President, Chief Commercialization Officer and Samit Hirawat, M.D., Executive Vice President, Chief Medical Officer, Global Drug Development, will answer questions about the company at 9:40 a.m. ET. Investors and the general public are invited to listen to a live webcast of the session at http://investor.bms.com. An archived edition of the session will be available later that day. About Bristol Myer

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE:BMY) today announced positive results from two pivotal Phase 3 trials evaluating deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, for the treatment of patients with moderate to severe plaque psoriasis. The POETYK PSO-1 and POETYK PSO-2 trials, which evaluated deucravacitinib 6 mg once daily, met both co-primary endpoints versus placebo, with significantly more patients achieving Psoriasis Area and Severity Index (PASI) 75 response and a static Physician's Global Assessment score of clear or almost clear (sPGA 0/1) after 16 weeks of treatment with deucravacitinib. Deucravacitinib was well tolerated wi

Bristol Myers Squibb (NYSE:BMY) today announced that the company will participate in a fireside chat at Bernstein's 37th Annual Strategic Decisions Virtual Conference, which will be webcast on Wednesday, June 2, 2021. Giovanni Caforio, M.D., Board Chair and Chief Executive Officer, will answer questions about the company at 10 a.m. ET. Investors and the general public are invited to listen to a live webcast of the session at http://investor.bms.com. An archived edition of the session will be available later that day. About Bristol Myers Squibb Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patie

Bristol Myers Squibb (NYSE:BMY) today announced that the company will host a virtual Investor Event on Tuesday, June 8, 2021 at 1 p.m. ET to discuss data presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. Company executives will provide an overview of data presented from the company's oncology portfolio and address questions from investors and analysts. Investors and the general public are invited to listen to a live webcast of the event at http://investor.bms.com. Materials related to the webcast will be available at the same website prior to the event. An archived edition of the Investor Event will be available later that day. About Bristol Myers Squibb

Bristol Myers Squibb (NYSE:BMY) today announced that the company will participate in a fireside chat at the UBS Global Healthcare Virtual Conference, which will be webcast on Tuesday, May 25, 2021. David Elkins, Executive Vice President, Chief Financial Officer and Samit Hirawat, M.D., Executive Vice President, Chief Medical Officer, Global Drug Development, will answer questions about the company at 1 p.m. ET. Investors and the general public are invited to listen to a live webcast of the session at http://investor.bms.com. An archived edition of the session will be available later that day. About Bristol Myers Squibb Bristol Myers Squibb is a global biopharmaceutical company whose mis

New analysis of EXPLORER-HCM trial assessing impact of mavacamten on patient's health status to be presented as late-breaking oral presentation Interim results of EXPLORER long-term extension study of mavacamten safety and efficacy data in patients with obstructive hypertrophic cardiomyopathy (oHCM) also to be presented Bristol Myers Squibb (NYSE:BMY) today announced that data from multiple studies across the company's clinical program investigating mavacamten in patients with obstructive hypertrophic cardiomyopathy (oHCM) will be presented at the upcoming American College of Cardiology's 70th Annual Scientific Session (ACC.21), being held virtually May 15 to May 17, 2021. Key presentati

Significantly more patients treated with deucravacitinib achieved PASI 75 and sPGA 0/1 compared to patients treated with placebo and Otezla at Week 16, with an increased benefit versus Otezla at Week 24 and maintained through Week 52 Deucravacitinib was well tolerated with a low rate of discontinuation due to adverse events Deucravacitinib is a first-in-class, oral, selective tyrosine kinase 2 (TYK2) inhibitor with a unique mechanism of action Results presented as late-breaking research at the 2021 American Academy of Dermatology Virtual Meeting Experience Bristol Myers Squibb (NYSE:BMY) today announced positive results from two pivotal Phase 3 trials evaluating deucravacitinib, an oral

NEW YORK--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE:BMY) today announced that the company will host a virtual Investor Event on Friday, April 23, 2021 at 10:30 a.m. ET to discuss data from the POETYK PSO-1 and POETYK PSO-2 Phase 3 trials of deucravacitinib in patients with moderate-to-severe psoriasis, which will be presented at the American Academy of Dermatology Virtual Meeting Experience (AAD VMX). Company executives will provide an overview of data presented and address questions from investors and analysts. Investors and the general public are invited to listen to a live webcast of the event at http://investor.bms.com. Materials related to the webcast will be available at t

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for mavacamten, an investigational, novel, oral, allosteric modulator of cardiac myosin, for patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of January 28, 2022. “HCM, which is the most common inherited heart disease, can be a chronic, debilitating, and progressive condition where patients may experience symptoms of shortness of breath, dizziness and fatigue as well as serious, life-altering complications, includ

NEW YORK--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the company will take part in a fireside chat at Barclays’ Virtual Global Healthcare Conference, which will be webcast on Tuesday, March 9, 2021. David Elkins, Executive Vice President, Chief Financial Officer will answer questions about the company at 3 p.m. ET. Investors and the general public are invited to listen to a live webcast of the session at http://investor.bms.com. Material related to the company’s presentation will be available at the same website at the start of the live webcast. An archived edition of the session will be available later that day. About Bristol Myers Squibb Bristol Mye